Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
  • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
  • A61K51/04—Organic compounds
  • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
  • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2121/00—Preparations for use in therapy
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2123/00—Preparations for testing in vivo

Definitions

• the invention relates to the use of complexes of all-cis-1,3,5-
• Triamino-2,4,6-cyclohexanetriol and its derivatives with radioactive ions Triamino-2,4,6-cyclohexanetriol and its derivatives with radioactive ions
• Metal isotopes for X-ray diagnostic purposes and in tumor therapy and for the production of agents for X-ray diagnostic purposes and for tumor therapy.
• the object of the invention is to provide new possibilities for X-ray diagnostic imaging and for tumor treatment.
• radioactive metals in particular radioactive metal cations with all-cis, 1,3,5-triamino-2,4,6-trihydroxycyclohexane and its derivatives, for X-ray diagnostic purposes and in tumor therapy or for the production of agents for X-ray diagnostic purposes and for tumor therapy.
• the complexes used according to the invention are preferably radioactive
• Underlying metal isotopes which are ⁇ , ß, or ⁇ emitters.
• radioactive isotopes that can be used are those of
• the ligands used for the complexes according to the invention are all-cis- 1,3,5-triamino-2,4,6-cyclohexanetriol and its derivatives, as they are
• R 1 , R 2 , R 3 , R 4 , R 5 or R 6 are the same or different and stand for hydrogen atoms, alkyl groups or -CO- alkyl groups
• the alkyl in the alkyl or -CO -Alkyl deficit has 1 to 18 carbon atoms
• the alkyl and -CO- alkyl groups can each independently contain one or more, identical or different functional groups, and their salts with inorganic or organic pharmacologically common acids and their quaternary ammonium salts of the general formula (II), (IIa) or (Ilb)
• R 9 independently of one another are the unsubstituted or substituted alkyl groups or -CO-alkyl groups defined above or all-cis- 1,3,5-tri-amino-2,4,6-trihydroxycyclohexane derivatives of the general formula
• substituents on the nitrogen atoms are independently H or CH 3 and preferably all CH 3 .
• radicals R 1 to R 6 in the ligands are alkyl or —CO— alkyl groups which are one or more, identical or different
• R 1 to R 9 may contain functional groups. Of the symbols R 1 to R 9, there is preferably at most one symbol on each nitrogen atom
• a preferred group of ligands are those in which all residues
• R 1 to R 6 or R 1 to R 9 are methyl or -COCH 3 groups.
• the alkyl groups or —CO-alkyl groups of the substituents R 1 to R 6 or R 1 to R 9 preferably have one or more functional groups which can coordinate with metal cations.
• Examples of functional groups on the alkyl groups or -CO-alkyl groups are -OH, -COOH or salts thereof, -CONH 2 , -CON (OH) R, where R represents an alkyl group having 1 to 6, in particular 1 to 4, carbon atoms , -OPO 3 H 2 and their salts, -PO 3 H 2 or their salts, -SR (in which R has the above meaning), and the esters of the above acids, -CN,
• Preferred examples are those of the ligands of the formulas (I), (II), (Ila) or (Ilb), in which one or more or all of the symbols R 1 to R 9 independently of one another have the following meaning:
• n 1, 2 or 3, and their salts; as well as those in which one or more or all of the symbols R 1 to R 9 independently of one another have the following meaning:
• n 1, 2 or 3, and their salts.
• a particularly preferred group of ligands are those of the formula (I), (II), (Ila) and ((Ilb), in which at least one of the radicals R 1 to R 6 and in particular in each case the radicals R 1 , R 3 and R 5 represent the group - (CH 2 ) n -COOH, in which n has the meaning from 1 to 3 and particularly preferably from 2.
• the remaining substituents R 2 , R 4 , R 6 and R 7 to R 9 are preferably Hydrogen or CH 3 , these remaining substituents preferably being the same
• Such compounds of the formula (I) are particularly well suited for tumor therapy.
• Complexes used are those that have positive charges, so that the complexes made from it are positively charged. Such complexes are particularly good, for example, for X-ray diagnostic purposes,
• the positive charges can either be caused by the quaternary nitrogen atoms of the compounds of the formula (II), (Ila),
• the positive charges can, for example, by
• Functional groups are alkyl groups with quaternary ammonium groups, such as trimethylamino groups or triethylamino groups, for example those
• the complexes used according to the invention are easily formed from aqueous solutions or suspensions of salts, hydroxides or oxides of the respective
• radioactive metals of interest and aqueous solutions or suspensions of the ligands.
• the aqueous solutions can be acidic, for example.
• amounts are used for this purpose such that 2 mol of ligands of the formula (I), (II), (Ila), (Ilb) or 1 mol of the formula (III) or (IV) are present per 1 mol of metal ion. A slight excess of the ligand is preferably used.
• Metals or metal cations can be replaced by corresponding non-radioactive isotopes.
• the complexes can be in the form of mixtures of
• Radioactive metals or metal cations and the radioactive metals or metal cations may be the same or different.
• radioactive iron isotopes they can be present together with non-radioactive iron. In the manufacture of such preparations, for example
• radioactive iron III ions occur.
• the complexes used according to the invention can be obtained from the manufacturer or
• positively charged complexes are preferably used.
• ⁇ - or Are spotlights it is particularly favorable to choose such complexes that ⁇ - or Are spotlights; ⁇ -emitters are preferably used for combating tumors, for example combating cancer.
• the complexes used according to the invention are used in the form of aqueous solutions; they can be used in various ways, particularly by intravenous administration.
• the nitrile was hydrolyzed by refluxing in concentrated hydrochloric acid for 6 hours.
• the all-cis-1,3,5-tris (2'ammoniopropionic acid) -2,4,6-cyclohexanetriol trichloride was obtained by concentrating on a rotary evaporator.
• the precipitated 59 ferri-all-cis-1,3,5-tris (2'-aminopropionic acid) -2,4,6-cyclohexanetriol was suction filtered through a G4 filter and then purified by dissolving in 0.1 M HCl and precipitation at pH 4.5. The product was finally dried under high vacuum. Because of spectroscopic
• the complex is soluble in or above a buffer with a physiological pH.
• the structural identity with the non-radioactively labeled preparation was determined on the basis of spectroscopic properties.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Physics & Mathematics (AREA)
• Optics & Photonics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (2)

Applications Claiming Priority (2)

Publications (1)

Family

ID=6413642

Family Applications (1)

Country Status (10)

Cited By (3)

Families Citing this family (1)

Citations (3)

• 1990
  • 1990-09-05 DE DE4028139A patent/DE4028139A1/de not_active Withdrawn
• 1991
  • 1991-09-05 EP EP91915523A patent/EP0504339A1/de not_active Withdrawn
  • 1991-09-05 AU AU84367/91A patent/AU658148B2/en not_active Ceased
  • 1991-09-05 CA CA002073050A patent/CA2073050A1/en not_active Abandoned
  • 1991-09-05 WO PCT/EP1991/001679 patent/WO1992004056A1/de not_active Application Discontinuation
  • 1991-09-05 PT PT98869A patent/PT98869A/pt not_active Application Discontinuation
  • 1991-09-05 KR KR1019920701057A patent/KR920702235A/ko not_active Application Discontinuation
  • 1991-09-05 JP JP3514779A patent/JPH05502456A/ja active Pending
  • 1991-09-05 MX MX9100967A patent/MX9100967A/es unknown
  • 1991-12-10 TW TW080109680A patent/TW197951B/zh active

Patent Citations (3)

Also Published As

Similar Documents

Legal Events